Understand the source comparison
Ipamorelin for Hair Growth Research Evidence: Comparison
In vitro dermal papilla cell cultures IGF-1 increased cell proliferation by 34% and upregulated β-catenin signaling (2017 Experimental Dermatology study) Isolated cells don't replicate intact follicle physiology, hormonal feedback, or immune interactions Mecha
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- In vitro dermal papilla cell cultures
- IGF-1 increased cell proliferation by 34% and upregulated β-catenin signaling (2017 Experimental Dermatology study)
- Isolated cells don't replicate intact follicle physiology, hormonal feedback, or immune interactions
- Mechanistic plausibility established but clinical relevance unproven
- Rodent (mouse) hair cycle models
- Systemic GH analogs accelerated anagen re-entry and increased hair shaft diameter
- Mice have synchronised hair cycles and lack androgen-driven follicle miniaturisation seen in human pattern baldness
- Species differences limit translational value for androgenetic alopecia
- Human GH replacement therapy (rhGH for deficiency states)
- Patients report improved skin quality and wound healing; hair regrowth not consistently documented
- Doses target physiological IGF-1 restoration, not supraphysiological peaks; confounded by overall health improvement
- No systematic evidence supporting hair restoration as a primary rhGH outcome
- Ipamorelin-specific human trials for hair loss
- Zero published randomised controlled trials exist as of 2026
- Complete absence of clinical efficacy and safety data in this indication
- Investigational only. No basis for therapeutic claims